Guillaume Costecalde

Elaia Partners SAS (Elaia) is an independent French private equity boutique which was founded in 2002. Named after the Greek word for olive tree, the symbol of resilience, longevity and prosperity, Elaia focuses on software technology companies. The firm is headquartered in Paris and manages Elaia Ventures, a French FCPR fund backed by financial institutions, industrial investors and family offices.

Academie des Technologies engages in the technology industry. The company was founded in December 2000 and is headquartered in Paris, France.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

Medicen Paris Region is a health competitiveness cluster based in the Île-de-France region. The French company aims to promote local industrialization and respond to health sovereignty challenges. The non-profit company offers various job opportunities that can be found on their website.

Part of Takara Holdings, Inc., Cellectis AB is a Swedish company that manufactures and distributes stem cell-related products. The company is based in Gothenburg, Sweden. Cellectis was acquired by Takara Bio, Inc. from Cellectis SA on September 04, 2014.

Bilhi Genetics SAS specializes in the development of predictive medicines. It offers products for hepatic fibrosis and skin scars. The company was founded by David Sourdive and Pierre Dessein in June 2012 and is headquartered in Marseille, France.

EnobraQ SAS develops yeast for the production of chemical compounds. The company was founded on November 13, 2015 and is headquartered in Ramonville-Saint-Agne, France.

Toulouse White Biotechnology Consortium provides industrial biotechnology solutions. The firm also offers collaborative research and development projects and technical services. The company was founded by Pierre Monsan in 2010 and is headquartered in Ramonville Saint Agne, France.

Part of Merck KGaA, Merck Biodevelopment SAS engages in research and development in other physical and natural sciences. The company is based in Lyon, France. The CEO of the French company is Didier Rosenberger.

Nextbiotix SAS operates as clinical-stage Biopharmaceutical Company, which develops probiotics. The company was founded by Benjamin Hadida, Harry Sokol, Philippe Langella and Patrick Gervais in 2016 and is headquartered in Dijon, France.

Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then.